Centerstone’s Ketamine/Esketamine Program for Treatment-Resistant Depression featured on news broadcast

Centerstone’s new therapy program for individuals seeking treatment for severe depression was featured recently on WFLA-TV.

Through the program, Centerstone can offer Spravato, a nasal spray that contains the FDA-approved medication Esketamine, and ketamine infusion therapy for people who have been treated for depression with no improvement in symptoms.

To learn more about this program, please go online to centerstone.org/esketamine. To view this video, please click here.